Rapid and Widespread Distribution of Intranasal Small Extracellular Vesicles Derived from Mesenchymal Stem Cells throughout the Brain Potentially via the Perivascular Pathway

Shen, Weiwei; You, Tongyao; Xu, Wenqing; Xie, Yanan; Wang, Yingzhe; Cui, Mei

doi:10.3390/pharmaceutics15112578

Cited by 4 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MSCs promote the production of IL-10 by macrophages, improving mitochondrial dysfunction in dorsal root ganglion (DRG) neurons, thus significantly reducing mechanical allodynia and spontaneous pain in mice [ 96 ]. The intranasal delivery of MSC-EVs has been observed to undergo axonal transport and cerebrospinal fluid circulation through the olfactory and trigeminal pathways, ultimately reaching the olfactory bulb, thalamus, hippocampus, subarachnoid space, and spinal cord in mice and rats [ 113 ]. Moreover, nasal delivery offers a non-invasive method for drug administration, which presents a lower risk of tissue injury and infection in comparison to intrathecal injection.…”

Section: Optimization Strategies For Msc-based Analgesia Therapymentioning

confidence: 99%

Optimization strategies for mesenchymal stem cell-based analgesia therapy: a promising therapy for pain management

Zhang,

Wu,

Wen

2024

Stem Cell Res Ther

View full text Add to dashboard Cite

Pain is a very common and complex medical problem that has a serious impact on individuals’ physical and mental health as well as society. Non-steroidal anti-inflammatory drugs and opioids are currently the main drugs used for pain management, but they are not effective in controlling all types of pain, and their long-term use can cause adverse effects that significantly impair patients’ quality of life. Mesenchymal stem cells (MSCs) have shown great potential in pain treatment. However, limitations such as the low proliferation rate of MSCs in vitro and low survival rate in vivo restrict their analgesic efficacy and clinical translation. In recent years, researchers have explored various innovative approaches to improve the therapeutic effectiveness of MSCs in pain treatment. This article reviews the latest research progress of MSCs in pain treatment, with a focus on methods to enhance the analgesic efficacy of MSCs, including engineering strategies to optimize the in vitro culture environment of MSCs and to improve the in vivo delivery efficiency of MSCs. We also discuss the unresolved issues to be explored in future MSCs and pain research and the challenges faced by the clinical translation of MSC therapy, aiming to promote the optimization and clinical translation of MSC-based analgesia therapy. Graphical Abstract

show abstract

Section: Optimization Strategies For Msc-based Analgesia Therapymentioning

confidence: 99%

Optimization strategies for mesenchymal stem cell-based analgesia therapy: a promising therapy for pain management

Zhang,

Wu,

Wen

2024

Stem Cell Res Ther

View full text Add to dashboard Cite

show abstract

Natural Killer Cell‐Derived Extracellular Vesicles as Potential Anti‐Viral Nanomaterials

Lim,

Ho,

Chen

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

In viral infections, natural killer (NK) cells exhibit anti‐viral activity by inducing apoptosis in infected host cells and impeding viral replication through heightened cytokine release. Extracellular vesicles derived from NK cells (NK‐EVs) also contain the membrane composition, homing capabilities, and cargo that enable anti‐viral activity. These characteristics, and their biocompatibility and low immunogenicity, give NK‐EVs the potential to be a viable therapeutic platform. This study characterizes the size, EV‐specific protein expression, cell internalization, biocompatibility, and anti‐viral miRNA cargo to evaluate the anti‐viral properties of NK‐EVs. After 48 hours of NK‐EV incubation in inflamed A549 lung epithelial cells, or conditions that mimic lung viral infections such as during COVID‐19, cells treated with NK‐EVs exhibit upregulated anti‐viral miRNA cargo (miR‐27a, miR‐27b, miR‐369‐3p, miR‐491‐5p) compared to the non‐treated controls and cells treated with control EVs derived from lung epithelial cells. Additionally, NK‐EVs effectively reduce expression of viral RNA and pro‐inflammatory cytokine (TNF‐α, IL‐8) levels in SARS‐CoV‐2 infected Vero E6 kidney epithelial cells and in infected mice without causing tissue damage while significantly decreasing pro‐inflammatory cytokine compared to non‐treated controls. Herein, our work elucidates the potential of NK‐EVs as safe, anti‐viral nanomaterials, offering a promising alternative to conventional NK cell and anti‐viral therapies.This article is protected by copyright. All rights reserved

show abstract

HucMSC extracellular vesicles increasing SATB 1 to activate the Wnt/β‐catenin pathway in 6‐OHDA‐induced Parkinson's disease model

He,

Li,

et al. 2024

IUBMB Life

View full text Add to dashboard Cite

Parkinson's disease (PD) is a degenerative disorder of the nervous system characterized by the loss of dopaminergic neurons and damage of neurons in the substantia nigra (SN) and striatum, resulting in impaired motor functions. This study aims to investigate how extracellular vesicles (EVs) derived from human umbilical cord mesenchymal stem cells (HucMSC) regulate Special AT‐rich sequence‐binding protein‐1 (SATB 1) and influence Wnt/β‐catenin pathway and autophagy in PD model. The PD model was induced by damaging SH‐SY5Y cells and mice using 6‐OHDA. According to the study, administering EVs every other day for 14 days improved the motor behavior of 6‐OHDA‐induced PD mice and reduced neuronal damage, including dopaminergic neurons. Treatment with EVs for 12 hours increased the viability of 6‐OHDA‐induced SH‐SY5Y cells. The upregulation of SATB 1 expression with EV treatment resulted in the activation of the Wnt/β‐catenin pathway in PD model and led to overexpression of β‐catenin. Meanwhile, the expression of LC3 II was decreased, indicating alterations in autophagy. In conclusion, EVs could mitigate neuronal damage in the 6‐OHDA‐induced PD model by upregulating SATB 1 and activating Wnt/β‐catenin pathway while also regulating autophagy. Further studies on the potential therapeutic applications of EVs for PD could offer new insights and strategies.

show abstract

Rapid and Widespread Distribution of Intranasal Small Extracellular Vesicles Derived from Mesenchymal Stem Cells throughout the Brain Potentially via the Perivascular Pathway

Cited by 4 publications

References 41 publications

Optimization strategies for mesenchymal stem cell-based analgesia therapy: a promising therapy for pain management

Optimization strategies for mesenchymal stem cell-based analgesia therapy: a promising therapy for pain management

Natural Killer Cell‐Derived Extracellular Vesicles as Potential Anti‐Viral Nanomaterials

HucMSC extracellular vesicles increasing SATB 1 to activate the Wnt/β‐catenin pathway in 6‐OHDA‐induced Parkinson's disease model

Contact Info

Product

Resources

About